Junod is a medicine used to treat the following conditions: - osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Junod reduces the risk of fractures in the spine and elsewhere in the body, including the hip; - bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Junod reduces the risk of fractures in the spine; - bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection. Junod contains the active substance denosumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Junod is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Junod is Prolia. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines).
Therapeutic Indication
### Therapeutic indication Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Junod significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Junod significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
M05BX04
ATC Item
denosumab
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| denosumab | N/A | 地舒单抗 |
EMA Name
Junod
Medicine Name
Junod
Aliases
N/ANo risk management plan link.
